Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
8 U3 N% H+ w# V+ k; b
+ g' B6 X2 d' H: ^* p c1 S% i2 s3 H0 d! c
Sub-category:
5 s" S1 {, D' B3 g( CMolecular Targets
$ Y6 w9 S, g! ]% N% [6 `! X8 E- F( ^$ |8 i/ ?9 a) L5 Z
3 z3 f; ?) R( vCategory:7 g- O6 r3 W2 M5 a
Tumor Biology
E/ A9 z" y5 |4 O5 e6 j& s+ k- k0 v8 p
# l3 A& c* C- ?3 n* J
Meeting:
, c6 I; A; O0 A2 O& T' {2011 ASCO Annual Meeting : A2 _: X+ x% Q% E6 I
6 b. }: C+ c) k7 @3 l9 i
) ?2 U- C) s2 |! `( bSession Type and Session Title:% V1 S8 t8 X( g" T; u
Poster Discussion Session, Tumor Biology - W% }, [4 c! x7 D: u4 \1 s- ~
$ P; L( t+ N# o6 ]) \" ^, B
& U+ |8 p4 ^+ t" V% F) ]: @" pAbstract No:$ B$ a$ O$ c" B w
10517 / D) }7 s8 ]; V
7 W/ j1 n+ {9 c/ u8 q0 N3 U* f
# c b6 W$ r& A' rCitation:
: ~4 k% M) _4 z# V/ [% dJ Clin Oncol 29: 2011 (suppl; abstr 10517)
$ ]: B. k. L6 S' s
' a! |6 i5 {# l2 E; a
' C- Q/ w) w H# \Author(s):
* i7 X1 j/ H' @5 UJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
# D& c4 `* l2 W6 ^! q" v k! D
% n0 {0 Q) J5 }) N$ j6 F# o- z2 C. d! I" A
/ B" b1 ^1 ^4 [& ZAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.9 I8 [# d. q3 {) I' n
9 f1 ~0 }9 G3 {2 Z
Abstract Disclosures+ r3 x- f* S7 J# S
! p8 h/ o+ \! y g* Z+ @8 V( b3 S9 O6 qAbstract:+ Y- ~0 K/ c# ]' J* \6 U+ T% n
5 z& p! ~0 X& N3 w
8 r: f" S( z2 J8 G& I# MBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
4 o, x! V6 F5 U4 e4 S; s4 G2 C5 d: |) Z2 M3 e
/ K8 V6 L. C9 E D F* Z, y |
显身卡
